Rapid-Acting Technologies and Novel Product types: Assessing Impact in Treatment-Resistant Depression Use cases
The treatment landscape for Major Depressive Disorder (MDD) is undergoing a significant transformation, driven by the emergence of rapid-acting Technologies. For decades, the therapeutic pathway relied on conventional selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) Product types, which often require weeks or even months to achieve...
0 Comments 0 Shares 147 Views 0 Reviews